Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex

Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated promising clinical activity in multiple cancers. However, resistance to PARP inhibitors remains a substantial clinical challenge. In the present study, we report that anaplastic lymphoma kinase (ALK) directly phosphorylates CDK9 at tyro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Yu-Yi, Chen, Mei-Kuang, Wei, Yongkun, Lee, Heng-Huan, Xia, Weiya, Wang, Ying-Nai, Yam, Clinton, Hsu, Jennifer L., Wang, Hung-Ling, Chang, Wei-Chao, Yamaguchi, Hirohito, Jiang, Zhou, Liu, Chunxiao, Li, Ching-Fei, Nie, Lei, Chan, Li-Chuan, Gao, Yuan, Wang, Shao-Chun, Liu, Jinsong, Westin, Shannon N., Lee, Sanghoon, Sood, Anil K., Yang, Liuqing, Hortobagyi, Gabriel N., Yu, Dihua, Hung, Mien-Chie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586872/
https://www.ncbi.nlm.nih.gov/pubmed/36253486
http://dx.doi.org/10.1038/s43018-022-00438-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586872/
https://www.ncbi.nlm.nih.gov/pubmed/36253486
http://dx.doi.org/10.1038/s43018-022-00438-2

Ejemplares similares